Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2024-06-13 Regulatory Filings
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
Regulatory Filings Classification · 100% confidence The document is a press release dated June 13, 2024, announcing the start of the clinical development program for a biosimilar candidate (FYB206) for Keytruda. It details the initiation of a Phase I clinical trial ("Dahlia") and mentions a parallel Phase III trial ("Lotus"). This type of announcement, focusing on the initiation of clinical studies for a drug candidate, is a specific corporate development update. It is not a full Annual Report (10-K), an Earnings Release (ER), or a formal Audit Report (AR). Since it details a significant step in the product pipeline, it is best classified as a general corporate announcement that falls under the broad category of Regulatory Filings (RNS) or potentially a specific type of corporate news. Given the options, and since it is a news release about a study start rather than a formal regulatory filing like a 10-K or a specific financial report, RNS (Regulatory Filings/General Regulatory Announcements) is the most appropriate fallback, although it is highly specific corporate news. However, none of the categories perfectly match 'Clinical Trial Initiation Announcement'. Since it is a news release disseminated via EQS News, and it doesn't fit the other specific financial/governance categories, RNS is the best fit as a general regulatory/corporate news dissemination.
2024-06-13 English
MS Pharma becomes Partner for the Commercialization of FYB203, Formycons Biosimilar Candidate to Eylea (Aflibercept), in the MENA Region
Regulatory Filings Classification · 100% confidence The document is explicitly labeled as a "News Details" item, contains a date (15 May 2024), and is formatted as a press release ("*Presse Release // May 15, 2024*"). It announces a specific business event: an exclusive licensing and supply agreement between Formycon's licensee (Klinge) and MS Pharma for commercialization rights. This type of material, announcing a significant business development or partnership outside of mandatory financial reporting periods (like 10-K or IR), typically falls under general regulatory announcements or news releases. Since it is not a formal financial report (10-K, IR, ER, MRQ) nor a specific corporate action like a dividend (DIV) or share transaction (POS), the most appropriate general category for a significant, non-financial-reporting-specific corporate announcement distributed via a news service (EQS-News) is Regulatory Filings (RNS), which serves as the fallback for miscellaneous corporate news that doesn't fit other specific codes. It is not an Earnings Release (ER) as it discusses a partnership, not financial results.
2024-05-15 English
Formycon reports on successful operating business and financial figures for the first quarter of 2024
Earnings Release Classification · 100% confidence The document explicitly states it reports on the 'first quarter of 2024' financial figures, uses keywords like 'Quarterly / Interim Statement/Quarter Results', and provides detailed financial metrics (revenue, EBITDA) for the period. This clearly identifies it as a comprehensive report covering a period shorter than a year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not just a brief announcement of a report (RPA) because it contains the full substance of the Q1 results and commentary, despite being distributed via a news service (EQS-News). Q1 2024
2024-05-08 English
Formycon invites to the Annual General Meeting on June 12, 2024 in Munich
Board/Management Information Classification · 99% confidence The document explicitly states, 'Formycon invites to the Annual General Meeting on June 12, 2024 in Munich' and uses the keyword 'AGM/EGM/Personnel' in the EQS header. The content details the agenda for the Annual General Meeting, including proposed resolutions for the Supervisory Board election and resignations. This directly corresponds to the definition of AGM Information (AGM-R). Although it is a press release announcing the meeting, the core content is the invitation and details of the AGM itself, making AGM-R a more specific fit than a general Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2024-05-07 English
Formycon hosts conference call on the results of the first quarter 2024
Report Publication Announcement Classification · 99% confidence The document is a press release dated May 2, 2024, announcing the details for an upcoming conference call scheduled for May 8, 2024, to discuss the results of the first quarter 2024. The key phrases are 'Formycon hosts conference call on the results of the first quarter 2024' and the provision of webcast/phone registration links. This document is not the actual earnings release (ER) or the comprehensive interim report (IR), but rather an announcement *about* the event where those results will be discussed. Since it is an announcement detailing an upcoming event (a conference call) where financial results will be presented, it most closely aligns with the definition of a Call Transcript (CT) if it were the transcript itself, or an Earnings Release (ER) if it contained the results. However, this document is purely an invitation/announcement for the call. Given the options, this type of announcement, which is essentially a news item about an upcoming investor event, often falls under the general 'Regulatory Filings' (RNS) category if it doesn't fit the specific 'Report Publication Announcement' (RPA) which usually announces the *release* of a static report. Since it is announcing a *call* to discuss results, and it is a standard news release format (EQS-News), RNS is the most appropriate general regulatory filing category for this type of corporate communication that isn't a primary financial statement or a transcript/presentation itself. However, if we consider the context of earnings events, it is an announcement related to the earnings process. Given the options, and recognizing it is a news announcement about an upcoming event, RNS is the safest fallback. If the document contained the actual Q1 results summary, it would be ER. Since it only announces the call, RNS is the best fit among the provided codes for a general corporate news announcement.
2024-05-02 English
Formycon AG: Dr. Marc Mikulcik, buy
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'. It details the acquisition of shares by Dr. Marc Mikulcik, including transaction dates, prices, volumes, and instrument identification codes. This content directly matches the definition for Director's Dealing (DIRS). The document length is short (2285 chars), but it is the primary disclosure itself, not an announcement of a separate report.
2024-04-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.